{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:47:39Z","timestamp":1792608459171,"version":"4.5.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"crossref","award":["LYY19H310010"],"award-info":[{"award-number":["LYY19H310010"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"crossref","award":["LYY20H310002"],"award-info":[{"award-number":["LYY20H310002"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Riociguat is a novel soluble guanylate cyclase stimulator, and has been widely used for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (CTEPH). Some studies found that riociguat had better effects on CTEPH and proved to be safe, but the results were not utterly consistent. Therefore, the purpose of this study was to comprehensively evaluate the efficacy and safety of riociguat in the treatment of CTEPH.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Randomized controlled trials on riociguat for the treatment of CTEPH were searched through such electronic databases as PubMed, Embase, Cochrane Library, Web of Science, China national knowledge internet, and Wanfang. The outcomes included exercise capacity, pulmonary hemodynamics, and side effects. The fixed-effects or random-effects models were used to analyze the pooled data, and heterogeneity was assessed by the <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup> test.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Four studies involving 520 patients were included in this meta-analysis. Compared with the placebo group, riociguat significantly improved the hemodynamic indexes and increased 6-min walking distance (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.0001, standardized mean difference (SMD)\u200a=\u200a\u22120.24, 95%CI \u22120.35 to \u22120.12; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.00001, SMD\u200a=\u200a0.52, 95%CI 0.33 to 0.71), and decreased the Borg dyspnea score (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.002, SMD\u200a=\u200a\u22120.31, 95%CI \u22120.51 to \u22120.12). In addition, riociguat could also significantly reduce the living with pulmonary hypertension scores and increase the EQ-5D scores (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.01, SMD=\u22120.23, 95%CI \u22120.42 to \u22120.05; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.00001, SMD\u200a=\u200a0.47, 95%CI 0.27 to 0.66), but there was no significant difference in the change level of N-terminal pro-hormone B-type natriuretic peptide in patients with riociguat (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.20, SMD\u200a=\u200a\u22120.24, 95%CI \u22120.61 to \u22120.13). The common adverse events of riociguat were dyspepsia and peripheral edema, and no other serious adverse reactions were observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>We confirmed that riociguat had better therapeutic effects in improving the hemodynamic parameters and exercise capacity in patients with CTEPH without inducing serious adverse events. This will provide a reasonable medication regimen for the treatment of CTEPH.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026211","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:11:00Z","timestamp":1622851860000},"page":"e26211","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension"],"prefix":"10.1097","volume":"100","author":[{"given":"Miaofa","family":"Ying","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9730-1357","authenticated-orcid":false,"given":"Mingxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"key":"R1-20250524","doi-asserted-by":"crossref","first-page":"S1789","DOI":"10.21037\/jtd.2019.08.54","article-title":"Evaluation and classification of pulmonary arterial hypertension","volume":"11","author":"Sahay","year":"2019","journal-title":"J Thorac Dis"},{"key":"R2-20250524","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1183\/16000617.00001115","article-title":"Chronic thromboembolic pulmonary hypertension: a distinct disease entity","volume":"24","author":"Lang","year":"2015","journal-title":"Eur Respir Rev"},{"key":"R3-20250524","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccm.2018.04.018","article-title":"Chronic thromboembolic pulmonary hypertension: an update","volume":"39","author":"Elwing","year":"2018","journal-title":"Clin Chest Med"},{"key":"R4-20250524","first-page":"1927","article-title":"Incidence and risk factors of chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism","volume":"7","author":"Yang","year":"2015","journal-title":"J Thorac Dis"},{"key":"R5-20250524","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.21037\/jtd.2018.07.106","article-title":"Incidence and risk factors of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a systematic review and meta-analysis of cohort studies","volume":"10","author":"Zhang","year":"2018","journal-title":"J Thorac Dis"},{"key":"R6-20250524","doi-asserted-by":"crossref","first-page":"160119","DOI":"10.1183\/16000617.0119-2016","article-title":"Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension","volume":"26","author":"Lang","year":"2017","journal-title":"Eur Respir Rev"},{"key":"R7-20250524","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12471-019-01352-6","article-title":"Safety and efficacy of balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension in the Netherlands","volume":"28","author":"van Thor","year":"2020","journal-title":"Neth Heart J"},{"key":"R8-20250524","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.resinv.2018.03.004","article-title":"Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: A systematic review","volume":"56","author":"Tanabe","year":"2018","journal-title":"Respir Invest"},{"key":"R9-20250524","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10741-019-09798-x","article-title":"Advances in targeted therapy for chronic thromboembolic pulmonary hypertension","volume":"24","author":"Zhang","year":"2019","journal-title":"Heart Fail Rev"},{"key":"R10-20250524","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2147\/DDDT.S117277","article-title":"Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension","volume":"11","author":"Lian","year":"2017","journal-title":"Drug Des Dev Ther"},{"key":"R11-20250524","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.cjca.2014.04.014","article-title":"Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"30","author":"Mielniczuk","year":"2014","journal-title":"Can J Cardiol"},{"key":"R12-20250524","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1183\/09031936.00182909","article-title":"Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study","volume":"36","author":"Ghofrani","year":"2010","journal-title":"Eur Respir J"},{"key":"R13-20250524","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijcard.2015.05.105","article-title":"Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"195","author":"Marra","year":"2015","journal-title":"Int J Cardiol"},{"key":"R14-20250524","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.2146\/ajhp130777","article-title":"Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"71","author":"Bishop","year":"2014","journal-title":"Am J Health-Syst Ph"},{"key":"R15-20250524","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"New Eng J Med"},{"key":"R16-20250524","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12931-018-0957-y","article-title":"Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)","volume":"19","author":"Marra","year":"2018","journal-title":"Resp Res"},{"key":"R17-20250524","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1183\/09031936.00087114","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)","volume":"45","author":"Simonneau","year":"2015","journal-title":"Eur Respir J"},{"key":"R18-20250524","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/heartasia-2015-010712","article-title":"Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison","volume":"8","author":"Wang","year":"2016","journal-title":"Heart Asia"},{"key":"R19-20250524","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1161\/CIRCULATIONAHA.106.661041","article-title":"Predictors of outcome in chronic thromboembolic pulmonary hypertension","volume":"115","author":"Bonderman","year":"2007","journal-title":"Circulation"},{"key":"R20-20250524","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1183\/09031936.00092008","article-title":"Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension","volume":"33","author":"Condliffe","year":"2008","journal-title":"Eur Respir J"},{"key":"R21-20250524","article-title":"Chronic thromboembolic pulmonary hypertension-management strategies and outcomes","volume":"12","author":"Ranka","year":"2019","journal-title":"J Cardiothor Vasc An"},{"key":"R22-20250524","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40262-017-0604-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of riociguat","volume":"57","author":"Frey","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"R23-20250524","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1086\/685404","article-title":"Population pharmacokinetics and the pharmacokinetic\/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension","volume":"6","author":"Saleh","year":"2016","journal-title":"Pulm Circ"},{"key":"R24-20250524","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/crj.13034","article-title":"A meta-analysis of randomized controlled trials in targeted treatments of chronic thromboembolic pulmonary hypertension","volume":"13","author":"Zhang","year":"2019","journal-title":"Clin Respir J"},{"key":"R25-20250524","doi-asserted-by":"crossref","first-page":"766720768","DOI":"10.1177\/2045894019826944","article-title":"Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension","volume":"9","author":"Sulica","year":"2019","journal-title":"Pulm circ"},{"key":"R26-20250524","first-page":"64","article-title":"Riociguat improves pulmonary hemodynamics in patients with inoperable chronic thromboembolic pulmonary hypertension","volume":"36","author":"Tsai","year":"2020","journal-title":"Acta Cardiol Sin"},{"key":"R27-20250524","first-page":"1444","article-title":"Impaired cardiac reserve and abnormal vascular load limit exercise capacity in chronic thromboembolic disease","volume":"12","author":"Claeys","year":"2019","journal-title":"JACC"},{"key":"R28-20250524","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/cvr\/cvx156","article-title":"Exercise and the right ventricle: a potential Achilles\u2019 heel","volume":"113","author":"La Gerche","year":"2017","journal-title":"Cardiovasc Res"},{"key":"R29-20250524","doi-asserted-by":"crossref","first-page":"1900276","DOI":"10.1183\/13993003.002762019","article-title":"Effect of domiciliary oxygen therapy on exercise capacity and quality of life in patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomised, placebo-controlled trial","volume":"54","author":"Ulrich","year":"2019","journal-title":"Eur Respir J"},{"key":"R30-20250524","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00408-019-00248-x","article-title":"Physical activity in incident patients with pulmonary arterial and chronic thromboembolic hypertension","volume":"197","author":"Saxer","year":"2019","journal-title":"Lung"},{"key":"R31-20250524","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12890-017-0563-7","article-title":"Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study","volume":"17","author":"Mclaughlin","year":"2017","journal-title":"BMC Pulm Med"},{"key":"R32-20250524","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/CIRCULATIONAHA.118.039360","article-title":"Association of N-Terminal pro brain natriuretic peptide and long-term outcome in patients with pulmonary arterial hypertension","volume":"139","author":"Chin","year":"2019","journal-title":"Circulation"},{"key":"R33-20250524","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2217\/bmm-2018-0348","article-title":"NT-proBNP plasma levels as biomarkers for pulmonary hypertension in healthy infants with respiratory syncytial virus infection","volume":"13","author":"Rodriguez-Gonzalez","year":"2019","journal-title":"Biomark Med"},{"key":"R34-20250524","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.rmed.2007.06.027","article-title":"Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension","volume":"101","author":"Suntharalingam","year":"2007","journal-title":"Resp Med"},{"key":"R35-20250524","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S2213-2600(16)30022-4","article-title":"Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial","volume":"4","author":"Simonneau","year":"2016","journal-title":"Lancet Respir Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T17:11:17Z","timestamp":1748106677000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026211"}},"subtitle":["A meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":35,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026211","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,4]]},"assertion":[{"value":"2020-10-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}